PR5-LL-CM01 demonstrated binding affinity to the active site of PRMT5 in silico, and it displayed anti-tumor effects in both in vitro and in vivo systems of pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) superior to the commercial inhibitor of PRMT5, EPZ01566627. Here, PRMT5 is linked to neoplasm.